Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy

The purpose of this study was to examine the influence of treatment frequency on visual acuity of patients with PDT treatment for subfoveal predominantly classic CNV related to pathological myopia. Retrospective case series. Thirty-seven patients with subfoveal predominantly classic CNV caused by pa...

Full description

Saved in:
Bibliographic Details
Published in:Graefe's archive for clinical and experimental ophthalmology 2006-10, Vol.244 (10), p.1262-1266
Main Authors: Maár, Noémi, Ergun, Erdem, Luksch, Alexandra, Stur, Michael
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Choroidal Neovascularization - drug therapy
Choroidal Neovascularization - etiology
Choroidal Neovascularization - physiopathology
Fovea Centralis
Humans
Middle Aged
Myopia
Myopia, Degenerative - complications
Myopia, Degenerative - physiopathology
Ophthalmology
Photochemotherapy
Photosensitizing Agents - therapeutic use
Porphyrins - therapeutic use
Retreatment
Retrospective Studies
Treatment Outcome
Visual Acuity - drug effects
Visual Acuity - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to examine the influence of treatment frequency on visual acuity of patients with PDT treatment for subfoveal predominantly classic CNV related to pathological myopia. Retrospective case series. Thirty-seven patients with subfoveal predominantly classic CNV caused by pathologic myopia and treated with PDT were included. All patients received a full ophthalmic examination, including best-corrected visual acuity, slit-lamp biomicroscopy, fundus photography and fluorescein angiography, before first treatment and every 3 months thereafter. Photodynamic therapy was performed according to standard protocol. Main outcome measurements were visual acuity and treatment frequency. The number of treatments received was 3.35+/-1.83 (average: 1-7). In 12 eyes (32.43%); the BCVA was stable or increased during the entire follow-up period. In eight eyes (21.62%), the BCVA decreased and did not return to the baseline values. A transient loss of visual acuity (over 3-9 months) with subsequent improvement in visual function was found in 68% (17 eyes). A gain of three or more lines compared with lowest BCVA was found in 56% (14 eyes). The number of treatments did not correlate with baseline BCVA, greatest linear dimension of CNV at baseline or with the change of BCVA from baseline. In cases with transient worsening of BCVA, the recovery of visual acuity correlated significantly with the number of treatments (r=-0.522, P
ISSN:0721-832X
1435-702X
DOI:10.1007/s00417-005-0246-6